曲美他嗪治疗慢性病毒性心肌炎心衰的效果及其对心功能的影响  

Clinical Efficacy and Impact on Cardiac Function of Trimetazidine for the Treatment of Heart Failure Induced by Chronic Viral Myocarditis

作　　者：陈华峰 

机构地区：[1]韶关市中医院重症医学科,广东韶关512026

出　　处：《临床医学工程》2016年第8期1063-1064,共2页Clinical Medicine & Engineering

摘　　要：目的探讨曲美他嗪治疗慢性病毒性心肌炎心衰的效果及其对心功能的影响。方法选择2014年6月至2015年7月我院收治的慢性病毒性心肌炎心衰患者80例为研究对象,随机分为两组各40例,对照组采用常规抗心衰治疗,研究组在对照组的基础上加用曲美他嗪进行治疗,观察比较两组治疗后的临床疗效以及心功能。结果治疗三个月后,研究组的左室射血分数(LVEF)、E/A比值均显著优于对照组(P<0.05),研究组的pro-BNP水平显著低于对照组(P<0.05)。研究组的总有效率为87.50%,对照组的总有效率为40.00%,组间差异具有统计学意义(P<0.05)。结论曲美他嗪可以明显改善慢性病毒性心肌炎心衰患者的心功能及预后,提高其生活质量,值得在临床上大力推广应用。Objective To explore the clinical efficacy and impact on the cardiac function of trimetazidine for the treatment of heart failure induced by chronic viral myocarditis. Methods A total of 80 cases of patients with heart failure induced by chronic viral myocarditis admitted to our hospital from June 2014 to July 2015 were selected in this study. All cases were randomly divided into two groups, with 40 cases in each group. The control group received routine anti-heart-failure therapy, while the study group received trimetazidine therapy on the basis of routine anti-heart-failure therapy. After therapy, the clinical effect and cardiac function were observed and compared between two groups. Results After 3 months of therapy, the left ventricular ejection fraction and E/A ratio of study group were significantly better than those of control group, and the pro-BNP level was significantly lower than that of control group, with statistical differences （P〈0.05）. The total effective rate of study group was 87.50%, significantly higher than 40.00% of control group, with statistical difference （P 〈0.05）. Conclusions Trimetazidine can effectively improve the cardiac function and prognosis of patients with heart failure induced by chronic viral myocarditis, so as to improve patients＇ quality of life, which is worthy of clinical promotion.

关 键 词：曲美他嗪 慢性病毒性心肌炎心衰 心功能 疗效 

分 类 号：R541.6[医药卫生—心血管疾病]